Phenoxybenzamine is an alpha-adrenergic blocker indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. It is available as capsules for oral use. MedsAcross supplies Phenoxybenzamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
INDICATION AND USAGE Phenoxybenzamine hydrochloride capsules are indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is excessive, it may be necessary to use a beta -blocking agent concomitantly.
Source: US FDA prescribing information
The dosage should be adjusted to fit the needs of each patient. Small initial doses should be slowly increased until the desired effect is obtained or the side effects from blockade become troublesome. After each increase, the patient should be observed on that level before instituting another increase. The dosage should be carried to a point where symptomatic relief and/or objective improvement are obtained, but not so high that the side effects from blockade become troublesome. Initially, 10 mg of phenoxybenzamine hydrochloride twice a day. Dosage should be increased every other day, usually to 20 mg to 40 mg 2 or 3 times a day, until an optimal dosage is obtained, as judged by blood pressure control. Long-term use of phenoxybenzamine is not recommended.
Source: US FDA prescribing information
Conditions where a fall in blood pressure may be undesirable, hypersensitivity to the phenoxybenzamine hydrochloride capsules, or any of its components.
Source: US FDA prescribing information
WARNING Phenoxybenzamine hydrochloride-induced alpha -adrenergic blockade leaves beta -adrenergic receptors unopposed. Compounds that stimulate both types of receptors may, therefore, produce an exaggerated hypotensive response and tachycardia.
Source: US FDA prescribing information
The following adverse reactions have been observed, but there are insufficient data to support an estimate of their frequency. Autonomic Nervous System*: Postural hypotension, tachycardia, inhibition of ejaculation, nasal congestion, miosis. *These so-called “side effects” are actually evidence of adrenergic blockade and vary according to the degree of blockade. Miscellaneous: Gastrointestinal irritation, drowsiness, fatigue.
Source: US FDA prescribing information
2 – Phenoxybenzamine hydrochloride may interact with compounds that stimulate both alpha- and beta- adrenergic receptors (i.e. epinephrine) to produce an exaggerated hypotensive response and tachycardia. Phenoxybenzamine hydrochloride blocks hyperthermia production by levarterenol, and blocks hypothermia production by reserpine.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Phenoxybenzamine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Phenoxybenzamine 10 mg capsuleOralGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 26 January 1953 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Phenoxybenzamine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Phenoxybenzamine and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Phenoxybenzamine on 26 January 1953, according to Drugs@FDA.
No listed presentation of Phenoxybenzamine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Phenoxybenzamine is classified under ATC code C04AX02 (Phenoxybenzamine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.